<html>
<body bgcolor="#e8e4ce" style="text-align: left; padding: 0; margin: 0;
background: #e8e4ce">
<table cellspacing="0" border="0" align="center" bgcolor="#e8e4ce"
style="width: 100%;" cellpadding="0">
<tbody>
<tr>
<td align="center" valign="top" style="font-family: Helvetica, Arial,
sans-serif;">
<table cellspacing="0" border="0" cellpadding="0" style="width: 600px;">
<tbody>
<tr>
<td align="left" style="padding: 0 0 20px; font-family: Helvetica, Arial,
sans-serif;">
<table cellspacing="0" border="0" align="left" cellpadding="0"
style="width: 600px;">
<tbody>
<tr>
<td align="left" valign="top" style="font-family: Helvetica, Arial,
sans-serif;">
<table border="0" align="left" cellspacing="0" bgcolor="#2d807c"
style="background-color: #2d807c; width: 100%; background-position: initial
initial; background-repeat: initial initial;">
<tbody>
<tr>
<td width="100%" height="103" valign="top" bgcolor="#2d807c"
style="padding: 10px; font-family: Helvetica, Arial, sans-serif;
background: #2d807c;">
<h1 align="left" style="font-weight: bold; padding: 0; font-size: 56px;
line-height: 76px; color: #ffe3a9; margin: 10px 0 0;">Nuvilex Inc.
(NVLX)</h1>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td align="left" style="padding: 0 0 20px; font-family: Helvetica, Arial,
sans-serif;">
<table cellspacing="0" border="0" align="left" bgcolor="#fff"
style="background-color: #ffffff; border: 1px solid #bddacb; width: 600px;
background-position: initial initial; background-repeat: initial initial;"
cellpadding="0">
<tbody>
<tr>
<td bgcolor="#fff" style="padding: 10px 10px 0; font-family: Helvetica,
Arial, sans-serif; background: #fff;" colspan="2">
<h2 style="padding: 6px 10px; background: #9ebbb0; font-weight: bold;
font-size: 18px; margin: 0; color: #fdfdfd;">FORBES Article Circulated
Lately Prominently Praises Nuvilex (NVLX)</h2>
</td>
</tr>
<tr>
<td valign="top" bgcolor="#fff" style="padding: 10px; font-family:
Helvetica, Arial, sans-serif; background: #fff;">
<p><b>As </b><b>issued</b><b> in FORBES in their Sept
23<sup>rd</sup> issue in a complete article investigating the speed at
which large pharmaceutical organizations such as Amgen, Celgene,
Roche/Genentech, and Eli Lilly are developing drugs to treat liver, kidney,
breast and pancreatic
cancers, </b><b>“</b><b>If <u>Nuvilex</u> were to
duplicate its phase II results in a phase III trial, the company’s
technology “would likely be the oncology treatment story of the
year,”<i> </i>states analyst Rob Goldman of Goldman Small Cap
Research in FORBES this week. FORBES went on to state, “The
existing gold standard is Eli Lilly’s (LLY) </b><a
href="http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=25&F=H"
target="scSearchLink" title="Search Link by Surf
Canyon"><b>Gemzar</b></a><b>, which has demonstrated a one-year survival
rate of 18% and a median total survival rate of 6.7 months.”
Goldman Small Cap Research says “In its phase II clinical studies,
the drug ifosfamide encapsulated via the Nuvilex technology lengthened the
survival time. <i><u>The average survival rate almost doubled and the
one-year survival time doubled compared with the historical data for
Gemzar.”</u></i></b></p>
<p><b> </b></p>
<p><b>FORBES, INVESTING – September 23, 2013</b></p>
<p><span style="font-size: small;"><b>Biotechs Have Returned to Favor
Amidst Abundance Of Positive Developments</b></span><b></b></p>
<p><b>The FDA also passed </b><a
href="http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=26&F=H"><b>Celgene</b></a><b> </b><a
href="http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=26&F=H"><b>CELG
+0.9%</b></a><b>’s (CELG) Abraxane for pancreatic cancer, for which
there are few successful treatment and survival time are significantly low.
“The present gold standard is Eli Lilly’s (LLY) </b><a
href="http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=25&F=H"
target="scSearchLink" title="Search Link by Surf
Canyon"><b>Gemzar</b></a><b>, which has confirmed a one-year survival time
of 18% and a average total survival rate of 6.7
months,</b><b> </b><b>says biotech analyst Robert Goldman of Goldman
Small-Cap Research.</b> <span style="font-size:
small; color: #ff0000;"><b><i>“This low survival rate has
encouraged</i></b><b> <i>a newer biopharmaceutical company
called <u>Nuvilex (NVLX)</u> to hunt for means to make existing
drugs substantially more effective, with lower dosage and less side
effects.</i></b><b><i>”</i></b></span></p>
<p><b>“With Nuvilex’s technology, live cells that convey high
amounts of the enzyme CYP 281 will be encapsulated in cellulose-based,
pin-head sized capsules implanted near the pancreas, and near to the tumor
itself,” says Goldman. A extensively circulated anti-cancer drug
Ifosfamide is then given intravenously, at low amounts, to the person
getting the encapsulated cells.</b></p>
<p><b>Goldman declares that in their phase II clinical studies, the drug
ifosfamide encapsulated by way of the Nuvilex technology increased the
survival time. “The average survival length just about doubled and
the one-year survival rate doubled compared with the historical data
for Gemzar,” says
Goldman. </b><b>“If <u>Nuvilex</u> were to echo its
phase II results in a phase III trial, the entity’s technology
“would possibly be the oncology treatment story of the
year,” </b><b>says Goldman.</b></p>
<p>To see the complete article in FORBES<b>, </b>please go
to http://www.forbes.com/sites/genemarcial/2013/09/23/biotechs-are-back-in-favor-amid-plethora-of-positive-developments/?partner=yahootix<br
/><br />10000 N Central ExpWay, Ste 400, Dallas, Tex. 75231 USA <a
href="http://notif.all-about-battery.com/link.php?M=6588707&N=4923&L=24&F=H"></a></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td align="left" style="padding: 0 0 10px; font-family: Helvetica, Arial,
sans-serif;">
<table cellspacing="0" border="0" align="left" bgcolor="#5b9b83"
style="background-color: #5b9b83; width: 600px; background-position:
initial initial; background-repeat: initial initial;" cellpadding="10">
<tbody>
<tr>
<td bgcolor="#1b4a15" style="font-family: Helvetica, Arial, sans-serif;
background: #1b4a15;" width="10"> </td>
<td bgcolor="#1b4a15" style="font-family: Helvetica, Arial, sans-serif;
background: #1b4a15;">
<h4 align="justify" style="padding: 0; font-size: 12px; color: #fff;
margin: 0;">The use of research materials circulated by the auth.or is done
at your own risk. You are encouraged to do your own research before making
any investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
distribution of these materials. You should presume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could end
in our trading securities at any time before, during, and/or after the
disbursement of this report.</h4>
</td>
<td bgcolor="#1b4a15" style="font-family: Helvetica, Arial, sans-serif;
background: #1b4a15;" width="10"> </td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
<p align="center"><a style="color: #000;"
href="http://notif.all-about-battery.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=4923">Remove
me from this newsletter</a></p>
</td>
</tr>
</tbody>
</table>
<img
src="http://notif.all-about-battery.com/open.php?M=6588707&L=54&N=4923&F=H&image=.jpg"
height="1" width="10"></body>
</html>